Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00136-4 ◽

2021 ◽

Author(s):

Assuntina G Sacco ◽

Ruifeng Chen ◽

Francis P Worden ◽

Deborah J L Wong ◽

Douglas Adkins ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial

Download Full-text

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Oral Oncology ◽

10.1016/j.oraloncology.2021.105192 ◽

2021 ◽

Vol 115 ◽

pp. 105192

Author(s):

Douglas R. Adkins ◽

Jin-Ching Lin ◽

Assuntina Sacco ◽

Jessica Ley ◽

Peter Oppelt ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30181-x ◽

2017 ◽

Vol 18 (5) ◽

pp. 631-639 ◽

Cited By ~ 154

Author(s):

Toshihiro Kudo ◽

Yasuo Hamamoto ◽

Ken Kato ◽

Takashi Ura ◽

Takashi Kojima ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Phase 2 ◽

Oesophageal Squamous Cell Carcinoma ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial

Download Full-text

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30755-5 ◽

2021 ◽

Vol 22 (4) ◽

pp. 463-475

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jérôme Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

First Line Treatment

Download Full-text

Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.11.140 ◽

2014 ◽

Vol 88 (2) ◽

pp. 507 ◽

Cited By ~ 1

Author(s):

A. Sacco ◽

J. Nor ◽

E. Belile ◽

A. Sukari ◽

D. Chepeha ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Phase 2 Trial

Download Full-text

Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1411 ◽

2021 ◽

pp. clincanres.1411.2021

Author(s):

Ezra E.W. Cohen ◽

Lisle Nabell ◽

Deborah J. Wong ◽

Terry Day ◽

Gregory A. Daniels ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Treatment Naïve

Download Full-text

nab-Paclitaxel and cisplatin followed by cisplatin and radiation (Arm 1) and nab-paclitaxel followed by cetuximab and radiation (Arm 2) for locally advanced head and neck squamous-cell carcinoma: a multicenter, non-randomized phase 2 trial

Medical Oncology ◽

10.1007/s12032-021-01479-w ◽

2021 ◽

Vol 38 (4) ◽

Author(s):

Peter Oppelt ◽

Jessica Ley ◽

Mackenzie Daly ◽

Jason Rich ◽

Randal Paniello ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Neck Squamous Cell Carcinoma ◽

Advanced Head ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

A Randomized, Open-Label, Multicenter, Global Phase 2 Study of Durvalumab (D), Tremelimumab (T), or D Plus T, in Patients With PD-L1 Low/Negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: CONDOR

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.12.021 ◽

2018 ◽

Vol 100 (5) ◽

pp. 1307 ◽

Cited By ~ 5

Author(s):

L. Siu ◽

C. Even ◽

R. Mesía ◽

A. Daste ◽

J. Krauss ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study

Download Full-text

Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 Study): an open-label, nonrandomized, multicenter, phase 2 trial

Annals of Oncology ◽

10.1016/j.annonc.2021.07.008 ◽

2021 ◽

Author(s):

B.G.M. Hughes ◽

E. Munoz-Couselo ◽

L. Mortier ◽

Å. Bratland ◽

R. Gutzmer ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Locally Advanced ◽

Cutaneous Squamous Cell Carcinoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial ◽

Multicenter Phase

Download Full-text

Abstract 5530: PD-L1 expression in patients screened for phase 2 head and neck squamous cell carcinoma clinical studies (HAWK and CONDOR)

10.1158/1538-7445.am2018-5530 ◽

2018 ◽

Cited By ~ 1

Author(s):

Sophie Wildsmith ◽

Marietta Scott ◽

Anita Midha ◽

Craig Barker ◽

Jessica Whiteley ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Clinical Studies ◽

Neck Squamous Cell Carcinoma ◽

Phase 2

Download Full-text

A Phase I/II, Open-Label, Dose Escalation Followed by Single-Arm Expansion to Assess the Safety and Efficacy of NT219 in Combination with Cetuximab in Patients with Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2019.11.144 ◽

2020 ◽

Vol 106 (5) ◽

pp. 1182-1183

Author(s):

O. Ronen ◽

M. Shickler ◽

H. Reuveni ◽

I. Israel ◽

I. Haviv ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Phase I ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Dose Escalation ◽

Neck Squamous Cell Carcinoma ◽

Open Label ◽

Safety And Efficacy ◽

Label Dose

Download Full-text